通脉益智胶囊对血管性痴呆患者微量元素的影响

目的:观察通脉益智胶囊对血管性痴呆患者微量元素的影响.方法:设立通脉益智胶囊(50例)和喜德镇(30例)两个治疗组,于治疗前后检测两组患者铜、硒、锌和铁等微量元素的含量.结果:通脉益智胶囊组治疗后铜和硒含量升高、锌和铁含量降低,与喜德镇组比较,差异有显著性(P＜0.05).结论:通脉益智胶囊具有可调整机体微量元素平衡,从而获得增强患者学习记忆能力、改善智能障碍的效果.     

四神止泻胶囊的制备及其质量控制

目的：制备四神止泻胶囊，并建立质量控制方法。方法：采用薄层色谱法鉴别肉豆蔻、五味子和吴茱萸三味药材，高效液相色谱法测定成品中补骨脂素和异补骨脂素的含量。结果：肉豆蔻、五味子和吴茱萸薄层色谱斑点清晰；成品三批中补骨脂素和异补骨脂素含量稳定。结论：四神止泻胶囊制备工艺合理，质量控制方法可行。     

高效液相色谱法测定生化产复康胶囊中的阿魏酸

目的：建立生化产复康胶囊中阿魏酸的含量测定方法。方法：采用高效液相色谱法，以kromasil C18柱为固定相，乙睛-0．085%磷酸溶液（17：83）为流动相，检测波长315nm，流速1．0ml／min，柱温35℃。结果：阿魏酸在0．076～0．228ug（r=0．9999）范围内线性关系良好，平均回收率为100．25％、RSD为1．84％。结论：本方法简便，准确，重现性好，可用于测定生化产复康胶囊中阿魏酸的含量。     

癫痫康对实验性癫痫家兔脑海马电图影响的研究

目的:观察癫痫康(党参、白术、茯苓、陈皮等)对海马内微量注射ZnSO4造成的实验性癫痫发作的影响.方法:以家兔行为,海马电图(EHG)的痫样放电频率,波幅为指标.结果:癫痫康大剂量、中剂量组可明显改善因ZnSO4注射引起的癫痫发作行为改变,降低EHG电位因ZnSO4注射引起的持续性棘慢波的频率和波幅.结论:癫痫康具有改善癫痫家兔脑海马电图作用.     

银黄胶囊质量标准研究

目的:建立银黄胶囊质量标准.方法:C1s柱(Hypersil ODS Agilent,4.6×200mm,5μm),流动相:甲醇与0.1%磷酸溶液进行梯度洗脱,检测波长为318mm,流速为1ml·min-1,柱温为室温.结果:绿原酸加样回收率为99.37%;RSD为0.35%;黄芩苷加样回收率为100.17%,RSD为1.23%.结论:方法简便、准确,可用于银黄胶囊的质量控制.     

阿莫西林胶囊溶出度的测定中自身对照液的影响研究

目的:使自身对照法测定阿莫西林胶囊溶出度的方法更加合理准确.方法:自身对照采用不同稀释步骤测定溶出度进行比较.结果:稀释步骤影响溶出度的测定.结论:方法更加准确,合理.     

复合氨基酸胶囊中水溶性维生素的含量测定

目的:建立复合氨基酸胶囊中5种水溶性维生素的含量测定方法.方法:采用高效液相色谱法,用乙腈与庚烷磺酸钠-磷酸钠的水溶液(pH=3.0)为流动相,流速1.0ml·min-1,色谱柱为C18(4.6×250mm,5μm),柱温40℃,检测波长为280nm,进样量为20μl.结果:维生素Bl、维生素B2、维生素B6、维生素C和烟酰胺分别在24.7～75.2μg·ml-1、15.0～44.9μg·ml-1、12.2～37.5μg·ml-1、99.2～299.9μg·ml-1和100.3～300.9μg·ml-1范围内呈线性关系,相关系数均为1.000,平均回收率均在100%±2%范围以内.RSD分别为0.19%、0.26%、0.46%、1.17%和0.52%.结论:本方法准确,简便,快捷,可以同时测定复合氨基酸胶囊中维生素B1、维生素B2、维生素B6、维生素C和烟酰胺的含量.     

Feasibility Study of Ultrasonographic Criteria for Microscopic and Macroscopic Extra-Thyroidal Extension Based on Thyroid Capsular Continuity and Tumor Contour in Patients with Papillary Thyroid Carcinomas

Our purpose was to evaluate the feasibility of using ultrasonographic criteria of thyroid capsular continuity and tumor contour to differentiate macroscopic extra-thyroidal extension (ETE) from microscopic ETE, as well as non-ETE from ETE. On ultrasonography, we evaluated thyroid capsular continuity (C0 = continuous, C1 = discontinuous, C2 = invisible), and thyroid tumor contour (P0 = in normal parenchyma, P1 = abutting, P2 = bulging), which were grouped into type 1–9 classifications. Either C1–2 or P1–2 was more prevalent in ETE than non-ETE. C1 and P2 tended to be associated with macroscopic ETE, whereas C0 and P1 were significantly associated with microscopic ETE. Types 6, 8 and 9 were more likely to have ETE than non-ETE; type 6 (C1 P2) and type 9 (C2 P2) were significantly associated with macroscopic ETE, whereas type 8 (C2 P1) was associated more with microscopic ETE. Macroscopic and microscopic ETE, as well as non-ETE and ETE, can be differentiated using these pre-operative ultrasonographic criteria.     

A Postmarketing Clinical Experience Study of Metadate® CD

Summary

Objective:The objective of the study was to investigate the effectiveness and safety of Metadate® CD (methylphenidate HCl, USP) Extended Release Capsules in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), in actual clinical practice.

Method:This was a multicenter, open-label, postmarketing study. Eligible patients were aged 6-17 with a diagnosis of ADHD and receiving either no treatment or maintenance treatment with another approved methylphenidate (MPH) product. Metadate® CD was administered once daily for 3 weeks, titrated against reported and observed symptoms. Clinical Global Impression (CGI) scores at Week 3 were used for the primary efficacy evaluation. Patient treatment satisfaction was determined by questionnaire at the final evaluation visit. Safety was assessed through adverse event reporting, laboratory tests and vital sign measurements.

Results: Overall, of the 308 patients in the Intent-To-Treat population, the majority (65%) demonstrated a positive response to Metadate® CD (defined as CGI Global Improvement rating of very much or much improved). In addition, patients previously treated with immediate-release or extended-release tablet formulations of MPH were successfully converted to Metadate® CD at a comparable dose. Most patients (87%) were very satisfied or moderately satisfied with study treatment, and among previously treated patients, 71% rated Metadate® CD as much better or better than their previous MPH treatment. Adverse events were consistent with current FDA-approved product labeling for Metadate® CD.

Conclusions: Metadate® CD is effective and well-tolerated in actual clinical use for ADHD.     

补中益气颗粒联合多糖铁复合物治疗妊娠期缺铁性贫血疗效和安全性分析

目的：探讨补中益气颗粒联合多糖铁复合物治疗妊娠期缺铁性贫血（IDA）的临床疗效。方法：将120例妊娠期IDA患者按照随机数字表法分为2组，每组60例。对照组给予多糖铁复合物治疗，研究组给予补中益气颗粒联合多糖铁复合物治疗，均用药4周。比较2组治疗前后红细胞（RBC）计数、血红蛋白（Hb）含量、平均红细胞血红蛋白含量（MCH）、血清铁（SI）、血清铁蛋白（SF）、铁调素和可溶性转铁蛋白受体（sTfR），以及2组治疗总有效率、不良反应和不良妊娠结局发生率。结果：治疗后研究组RBC、Hb、MCH、SI和SF均高于对照组，铁调素和sTfR低于对照组，治疗总有效率高于对照组，差异均有统计学意义（均P＜0.05）。2组不良反应发生率和不良妊娠结局发生率差异无统计学意义（P＞0.05）。结论：补中益气颗粒联合多糖铁复合物可有效改善铁代谢，治疗妊娠期IDA效果显著，安全性较好。